BackAIM ImmunoTech Overview

AIM ImmunoTech Intangible Assets

Track AIM ImmunoTech's intangible assets ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$0.00
↓ 100.00% YoYΔ $-2.17M vs prior year quarter

Peer trimmed avg / median

Loading

AIM ImmunoTech Intangible Assets History

Loading

AIM ImmunoTech vs. peers: Intangible Assets Comparison

Loading

AIM ImmunoTech Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AIM ImmunoTech (AIM) FAQ

AIM ImmunoTech posts a intangible assets of $0 as of June 2026. That compares with $2.2M in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, AIM ImmunoTech's intangible assets was $2.2M. The latest reading is $0 — a 100.0% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Intangible Assets is one piece of AIM ImmunoTech's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AIM's intangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AIM ImmunoTech's other metric pages and overview cover the third.

Judging AIM ImmunoTech against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in intangible assets easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.